Evidence-based Medicine
Video: Keeping up with Medical Literature and Being a Better Reader
29 Jun, 2020 | 09:01h | UTCKeeping up with medical literature and being a better reader, by Vinay Prasad, MD MPH
Editorial: Commercial Influence and Covid-19
25 Jun, 2020 | 08:18h | UTCCommercial influence and covid-19 – The BMJ
Study Commentary: Dexamethasone & COVID – A Study in Immunopathology, Evidence-based Medicine, and Ourselves
24 Jun, 2020 | 03:26h | UTC
[Preprint] Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report
23 Jun, 2020 | 08:47h | UTCEffect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report – medRxiv
Article press release from a few days ago: Dexamethasone Reduces Death by Up to One Third in Patients with Severe COVID-19
Related Commentary on Twitter
Kudos to @MartinLandray and team, including all patients, practitioners, administrators, funders & researchers. Amazing study. This is the new standard about how to move quickly, thoughtfully and effectively in research. Now @medrxivpreprint. Pls comment. https://t.co/0MBY13Uxvc pic.twitter.com/fFx3166nCJ
— Harlan Krumholz (@hmkyale) June 22, 2020
[Abstract Only] Does Tweeting Improve Citations? One-Year Results from the TSSMN Prospective Randomized Trial
21 Jun, 2020 | 23:26h | UTC
Related Commentary on Twitter
On using twitter to spread science:
RCT of 112 papers randomly chosen to be shared on twitter by a group of surgeons w ~58K followers (or to not be shared). Papers that were tweeted had 4x more citations a year later. NB @EndoSurgSF @jackhttps://t.co/6toVbAcCq4 pic.twitter.com/UJraiK9zkP
— Nicholas A. Christakis (@NAChristakis) June 15, 2020
The Pandemic Reality of COVID-19 Clinical Trials
18 Jun, 2020 | 08:52h | UTC
COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance
18 Jun, 2020 | 08:54h | UTC
Huge Open-access Journal Deal Inked by University of California and Springer Nature
18 Jun, 2020 | 08:51h | UTCHuge open-access journal deal inked by University of California and Springer Nature – Science
Related: UC Terminates Subscriptions with World’s Largest Scientific Publisher in Push for Open Access (several resources on the subject)
Guideline and Checklist for Reporting Randomized Trials that Use an Adaptive Design
18 Jun, 2020 | 08:50h | UTC
Related Commentary on Twitter
https://twitter.com/bmj_latest/status/1273352249134198789
Video: Coronavirus Q&A: Clinical Update with Carlos del Rio, MD
16 Jun, 2020 | 08:21h | UTCCoronavirus Q&A: Clinical Update with Carlos del Rio, MD
Analysis: Shifting, Overlapping and Expanding Use of “Precision Oncology” Terminology
16 Jun, 2020 | 07:46h | UTC
Opinion: John Ioannidis and Medical Tribalism in the Era of Covid-19
12 Jun, 2020 | 09:21h | UTCOpinion: John Ioannidis and Medical Tribalism in the Era of Covid-19 – Undark
“The critical questions the Stanford professor is raising about Covid-19 have gotten lost amid partisan bickering”
“Ioannidis, right or wrong, has raised difficult questions, in the best tradition of science. Silencing him is an enormous risk to take” say @JeanneLenzer1 & @ShannonBrownlee https://t.co/VCh9fKD5qy pic.twitter.com/tSbzFBHKmq
— Maryanne Demasi, PhD (@MaryanneDemasi) June 11, 2020
MIT, Guided by Open Access Principles, Ends Elsevier Negotiations
12 Jun, 2020 | 08:57h | UTCMIT, guided by open access principles, ends Elsevier negotiations – MIT News
Related: UC Terminates Subscriptions with World’s Largest Scientific Publisher in Push for Open Access (several resources on the subject)
Reporting of Financial Conflicts of Interest by Canadian Clinical Practice Guideline Producers
11 Jun, 2020 | 09:22h | UTC
The Pandemic Mixed up What Scientists Study – and Some Won’t go Back
8 Jun, 2020 | 04:26h | UTCThe pandemic mixed up what scientists study – and some won’t go back – Nature
Lancet, New England Journal Retract Covid-19 Studies, Including one That Raised Safety Concerns About Malaria Drugs
5 Jun, 2020 | 05:07h | UTCScience: Two elite medical journals retract coronavirus papers over data integrity questions
Challenge Trials—Could Deliberate Coronavirus Exposure Hasten Vaccine Development?
5 Jun, 2020 | 05:01h | UTCChallenge Trials—Could Deliberate Coronavirus Exposure Hasten Vaccine Development? – JAMA
Related: Opinion: Ethical Guidelines for Deliberately Infecting Volunteers with COVID-19 to Speed Vaccine Development (other commentaries on the subject)
Scientists’ Worlds Will Shrink in the Wake of the Pandemic
5 Jun, 2020 | 04:55h | UTCScientists’ worlds will shrink in the wake of the pandemic – Nature
The Coronavirus Outbreak Could Make It Quicker and Easier to Trial Drugs
5 Jun, 2020 | 04:54h | UTCThe coronavirus outbreak could make it quicker and easier to trial drugs – Nature
Will the Pandemic Permanently Alter Scientific Publishing?
4 Jun, 2020 | 05:01h | UTCWill the pandemic permanently alter scientific publishing? – Nature
How Scientific Conferences Will Survive the Coronavirus Shock
4 Jun, 2020 | 04:59h | UTCHow scientific conferences will survive the coronavirus shock – Nature
Expression of Concern Published by the NEJM Regarding the Study on the Effect of Preexisting Treatment with ACE Inhibitors and ARBs on Covid-19
3 Jun, 2020 | 03:46h | UTCSee also: An open letter to Mehra et al and The New England Journal of Medicine – Zenodo
Commentary: Top medical journals raise concerns about data in two studies related to Covid-19 – STAT
“We have asked the authors to provide evidence that the data are reliable. In the interim and for the benefit of our readers, we are publishing this Expression of Concern about the reliability of their conclusions.”
Expression of Concern Published by The Lancet Regarding the Paper on Hydroxychloroquine and Chloroquine Published on May 22, 2020
3 Jun, 2020 | 03:51h | UTCSee also: An Open Letter to Mehra et al and The Lancet (further commentaries on the subject)
Commentary: Top medical journals raise concerns about data in two studies related to Covid-19 – STAT
“we are issuing an Expression of Concern to alert readers to the fact that serious scientific questions have been brought to our attention. We will update this notice as soon as we have further information.”
Remdesivir Shows Modest Improvement in Moderate COVID-19 Patients
2 Jun, 2020 | 04:59h | UTC- Gilead’s remdesivir shows modest improvement in moderate COVID-19 patients – Reuters
- Expert reaction to press release announcing results of stage 3 trial of Gilead’s antiviral remdesivir in moderate patients – Science Media Centre
- Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show – STAT
An Open Letter to Mehra et al and The Lancet
1 Jun, 2020 | 03:58h | UTCAn open letter to Mehra et al and The Lancet – Zenodo
See also: Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere – The Scientist AND A Study Out of Thin Air – Medicine (Un)Censored